New data demonstrate racial and ethnic disparities in access to prescription medications in persons with chronic liver disease in the USA. Here, we discuss potential health equity solutions that address structural and social determinants of health to mitigate liver health inequities in access to liver disease pharmacotherapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
World Health Organization. Health equity. WHO https://www.who.int/health-topics/health-equity (2022).
Tapper, E. B., Essien, U. R., Zhao, Z., Ufere, N. N. & Parikh, N. D. Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States. J. Hepatol. https://doi.org/10.1016/j.jhep.2022.02.010 (2022).
Essien, U. R., Dusetzina, S. B. & Gellad, W. F. A policy prescription for reducing health disparities-achieving pharmacoequity. JAMA 326, 1793–1794 (2021).
Marcus, J. L. et al. Disparities in initiation of direct-acting antiviral agents for hepatitis C virus infection in an insured population. Public Health Rep. 133, 452–460 (2018).
Wang, T. et al. Healthcare disparities identified between Hmong and other Asian origin groups living with chronic hepatitis B infection in Sacramento County 2014–2017. J. Community Health 45, 412–418 (2020).
Gordon, S. C. et al. Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis. Am. J. Gastroenterol. 115, 262–270 (2020).
Ahn, J. C. et al. Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology https://doi.org/10.1002/hep.32527 (2022).
Jacobs, D. B. & Sommers, B. D. Using drugs to discriminate — adverse selection in the insurance marketplace. N. Engl. J. Med. 372, 399–402 (2015).
Ahn, S. & Corlette, S. State Efforts to Lower Consumer Cost-Sharing for High-Cost Prescription Drugs: Stakeholder Perspectives (Urban Institute, 2017).
Guadamuz, J. S. et al. Fewer pharmacies in Black and Hispanic/Latino neighborhoods compared with white or diverse neighborhoods, 2007-15. Health Aff. 40, 802–811 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Kardashian, A., Nephew, L.D. Achieving health equity in liver disease pharmacotherapy. Nat Rev Gastroenterol Hepatol 19, 489–490 (2022). https://doi.org/10.1038/s41575-022-00632-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-022-00632-8